Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 7,471,563 |
|
|||||
| News | - | ||||||
| Day High | 22.24 | Low High |
|||||
| Day Low | 20.69 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Exelixis Inc | EXEL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.54 | -6.54% | 21.925 | 15:31:21 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 21.64 | 20.69 | 22.24 | 21.925 | 23.46 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 60,716 | 7,471,563 | US$ 21.30 | US$ 159,153,863 | - | 18.21 - 24.34 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:20:00 | priorref | 9,780 | US$ 21.925 | USD |
Exelixis (EXEL) Options Flow Summary
Exelixis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.65B | 303.19M | - | 1.83B | 207.77M | 0.69 | 31.99 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Exelixis News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EXEL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 23.20 | 23.89 | 20.69 | 23.61 | 1,690,514 | -1.28 | -5.50% |
| 1 Month | 23.34 | 23.955 | 20.69 | 23.15 | 1,894,290 | -1.42 | -6.06% |
| 3 Months | 21.09 | 24.07 | 20.015 | 22.39 | 2,289,206 | 0.835 | 3.96% |
| 6 Months | 20.64 | 24.34 | 19.20 | 22.31 | 2,175,245 | 1.29 | 6.23% |
| 1 Year | 18.30 | 24.34 | 18.21 | 21.24 | 2,308,776 | 3.63 | 19.81% |
| 3 Years | 24.68 | 25.77 | 14.87 | 19.60 | 2,347,393 | -2.76 | -11.16% |
| 5 Years | 19.78 | 27.90 | 13.67 | 20.10 | 2,457,923 | 2.15 | 10.84% |
Exelixis Description
| Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
